Jazz Pharmaceuticals PLC Company Profile (NASDAQ:JAZZ)

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC logoJazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: JAZZ
  • CUSIP: G5087110
Key Metrics:
  • Previous Close: $121.48
  • 50 Day Moving Average: $127.22
  • 200 Day Moving Average: $139.40
  • 52-Week Range: $108.50 - $160.00
  • Trailing P/E Ratio: 21.36
  • Foreward P/E Ratio: 14.34
  • P/E Growth: 0.68
  • Market Cap: $7.35B
  • Outstanding Shares: 60,532,000
  • Beta: 0.93
Profitability:
  • Net Margins: 25.46%
  • Return on Equity: 28.39%
  • Return on Assets: 13.29%
Debt:
  • Debt-to-Equity Ratio: 0.67%
  • Current Ratio: 5.43%
  • Quick Ratio: 5.28%
Additional Links:
Companies Related to Jazz Pharmaceuticals PLC:

Analyst Ratings

Consensus Ratings for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) (?)
Ratings Breakdown: 2 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $185.00 (52.29% upside)

Analysts' Ratings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Show:
DateFirmActionRatingPrice TargetDetails
9/27/2016Goldman Sachs Group Inc.Reiterated RatingBuy$195.00 -> $187.00View Rating Details
9/15/2016MizuhoReiterated RatingBuy$185.00View Rating Details
9/8/2016BMO Capital MarketsReiterated RatingOutperform$193.00 -> $195.00View Rating Details
9/7/2016Leerink SwannReiterated RatingOutperform$202.00View Rating Details
8/25/2016Janney Montgomery ScottInitiated CoverageNeutralView Rating Details
8/11/2016Deutsche Bank AGReiterated RatingBuy$155.00 -> $158.00View Rating Details
8/10/2016Barclays PLCReiterated RatingBuy$200.00View Rating Details
8/10/2016Piper Jaffray Cos.Lower Price TargetOverweight$188.00 -> $178.00View Rating Details
6/18/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
6/2/2016SunTrust Banks Inc.Reiterated RatingBuy$200.00 -> $210.00View Rating Details
4/5/2016Canaccord GenuityReiterated RatingBuy$170.00View Rating Details
4/1/2016Northland SecuritiesReiterated RatingOutperform$175.00View Rating Details
3/19/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
2/24/2016Stifel NicolausLower Price TargetBuy$225.00 -> $200.00View Rating Details
11/25/2015Sanford C. BernsteinInitiated CoverageMarket Perform$160.00View Rating Details
11/10/2015Cowen and CompanyReiterated RatingBuyView Rating Details
5/26/2015GuggenheimBoost Price TargetBuy$210.00 -> $220.00View Rating Details
5/11/2015Cantor FitzgeraldSet Price TargetBuy -> Hold$175.00 -> $165.00View Rating Details
3/27/2015Citigroup Inc.Initiated CoverageBuy$195.00View Rating Details
11/5/2014R. F. LaffertyUpgradeNeutral -> Buy$200.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/9/2016Q216$2.80$2.63$376.40 million$381.00 millionViewN/AView Earnings Details
5/10/2016Q1$2.31$2.26$338.86 million$336.00 millionViewListenView Earnings Details
2/23/2016Q415$2.60$2.60$349.98 million$340.90 millionViewListenView Earnings Details
11/9/2015Q315$2.56$2.52$348.15 million$340.90 millionViewListenView Earnings Details
8/5/2015Q215$2.41$2.41$335.58 million$333.70 millionViewListenView Earnings Details
5/7/2015Q115$2.15$1.99$309.50 million$309.30 millionViewListenView Earnings Details
2/24/2015Q414$2.30$2.44$319.74 million$328.10 millionViewListenView Earnings Details
11/4/2014Q314$2.23$2.33$302.90 million$306.58 millionViewListenView Earnings Details
8/5/2014Q214$1.92$2.05$273.39 million$291.23 millionViewListenView Earnings Details
5/8/2014Q114$1.79$1.61$254.86 million$247.00 millionViewListenView Earnings Details
2/25/2014Q413$1.78$1.72$238.12 million$235.80 millionViewListenView Earnings Details
11/5/2013Q313$1.67$1.78$227.38 million$232.20 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.52$1.43$208.71 million$208.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.35$1.37$189.92 million$196.20 millionViewListenView Earnings Details
2/26/2013Q4 2012$1.41$1.53$183.80 million$183.70 millionViewListenView Earnings Details
11/8/2012Q312$1.31$1.29$178.57 million$175.50 millionViewN/AView Earnings Details
8/7/2012$1.05$1.09ViewN/AView Earnings Details
5/8/2012$0.90$0.91ViewN/AView Earnings Details
11/1/2011$0.89$0.94ViewN/AView Earnings Details
7/28/2011$0.67$0.82ViewN/AView Earnings Details
5/3/2011$0.57$0.59ViewN/AView Earnings Details
3/7/2011$0.60$0.63ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Current Year EPS Consensus Estimate: $6.29 EPS
Next Year EPS Consensus Estimate: $8.47 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$1.39$1.48$1.44
Q2 20161$1.92$1.92$1.92
Q3 20164$1.88$2.16$2.01
Q4 20162$2.38$2.70$2.54
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 88.25%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/19/2016Michael Patrick MillerSVPSell200$126.17$25,234.00View SEC Filing  
8/25/2016Seamus MulliganDirectorSell27,968$128.32$3,588,853.76View SEC Filing  
8/16/2016Paul TreacySVPSell1,292$137.47$177,611.24View SEC Filing  
8/15/2016Michael Patrick MillerSVPSell100$136.45$13,645.00View SEC Filing  
8/15/2016Rick E WinninghamDirectorSell633$136.45$86,372.85View SEC Filing  
8/12/2016Karen L SmithInsiderBuy608$137.10$83,356.80View SEC Filing  
8/9/2016Bruce C. CozaddCEOSell1,000$150.00$150,000.00View SEC Filing  
8/9/2016Russell J. CoxCOOSell4,000$148.66$594,640.00View SEC Filing  
7/15/2016Michael Patrick MillerSVPSell100$142.43$14,243.00View SEC Filing  
7/13/2016Karen L SmithCMOBuy580$143.63$83,305.40View SEC Filing  
6/15/2016Michael Patrick MillerSVPSell100$149.64$14,964.00View SEC Filing  
6/13/2016Karen L SmithCMOBuy557$149.61$83,332.77View SEC Filing  
5/16/2016Heather Ann McsharryDirectorSell697$145.20$101,204.40View SEC Filing  
5/16/2016Michael Patrick MillerSVPSell100$145.20$14,520.00View SEC Filing  
4/25/2016Karen J WilsonSVPSell604$160.00$96,640.00View SEC Filing  
4/15/2016Michael Patrick MillerSVPSell100$145.79$14,579.00View SEC Filing  
4/13/2016Karen J WilsonSVPSell5,007$150.00$751,050.00View SEC Filing  
4/12/2016Russell J CoxCOOSell4,000$136.98$547,920.00View SEC Filing  
4/7/2016Karen J WilsonSVPSell2,161$140.90$304,484.90View SEC Filing  
3/15/2016Michael Patrick MillerSVPSell100$129.17$12,917.00View SEC Filing  
3/8/2016Bruce C CozaddCEOSell2,500$126.04$315,100.00View SEC Filing  
2/29/2016Paul TreacySVPSell354$123.48$43,711.92View SEC Filing  
2/23/2016Seamus MulliganDirectorSell27,968$122.71$3,431,953.28View SEC Filing  
2/16/2016Michael Patrick MillerSVPSell100$115.63$11,563.00View SEC Filing  
2/10/2016Patrick G EnrightDirectorSell10,000$117.92$1,179,200.00View SEC Filing  
2/9/2016Bruce C CozaddCEOSell2,500$111.37$278,425.00View SEC Filing  
1/15/2016Michael Patrick MillerSVPSell100$122.66$12,266.00View SEC Filing  
1/12/2016Bruce C CozaddCEOSell2,500$123.81$309,525.00View SEC Filing  
1/5/2016Patrick G EnrightDirectorSell10,000$138.09$1,380,900.00View SEC Filing  
12/15/2015Michael Patrick MillerSVPSell100$136.99$13,699.00View SEC Filing  
12/8/2015Bruce C CozaddCEOSell2,500$139.72$349,300.00View SEC Filing  
12/2/2015Patrick G EnrightDirectorSell10,424$146.67$1,528,888.08View SEC Filing  
11/23/2015Seamus MulliganDirectorSell27,968$145.86$4,079,412.48View SEC Filing  
11/10/2015Bruce C CozaddCEOSell2,500$128.53$321,325.00View SEC Filing  
11/10/2015Patrick G EnrightDirectorSell10,000$135.29$1,352,900.00View SEC Filing  
10/21/2015Suzanne Sawochka HooperEVPSell2,000$125.00$250,000.00View SEC Filing  
10/13/2015Bruce C CozaddCEOSell2,500$131.50$328,750.00View SEC Filing  
10/5/2015Patrick G EnrightDirectorSell10,000$133.79$1,337,900.00View SEC Filing  
9/25/2015Michael Patrick MillerSVPSell100$145.23$14,523.00View SEC Filing  
9/8/2015Bruce C. CozaddCEOSell2,500$163.07$407,675.00View SEC Filing  
9/1/2015Patrick G EnrightDirectorSell10,000$165.99$1,659,900.00View SEC Filing  
7/14/2015Bruce C CozaddCEOSell5,000$177.79$888,950.00View SEC Filing  
7/14/2015Suzanne Sawochka HooperEVPSell4,000$177.79$711,160.00View SEC Filing  
7/6/2015Patrick G EnrightDirectorSell10,000$177.11$1,771,100.00View SEC Filing  
6/9/2015Bruce C CozaddCEOSell5,000$173.16$865,800.00View SEC Filing  
6/9/2015Suzanne Sawochka HooperEVPSell4,000$173.16$692,640.00View SEC Filing  
6/2/2015Karen J WilsonSVPSell5,751$179.59$1,032,822.09View SEC Filing  
6/1/2015Karen J WilsonSVPSell5,494$179.57$986,557.58View SEC Filing  
4/14/2015Bruce C CozaddCEOSell5,000$181.45$907,250.00View SEC Filing  
4/14/2015Suzanne Sawochka HooperEVPSell4,000$181.45$725,800.00View SEC Filing  
3/25/2015Seamus MulliganDirectorSell50,000$174.59$8,729,500.00View SEC Filing  
1/5/2015Patrick G EnrightDirectorSell10,000$160.25$1,602,500.00View SEC Filing  
12/26/2014Seamus MulliganDirectorSell50,000$163.40$8,170,000.00View SEC Filing  
12/12/2014Patrick G EnrightDirectorSell2,343$170.98$400,606.14View SEC Filing  
12/9/2014Bruce C CozaddCEOSell5,000$178.79$893,950.00View SEC Filing  
12/9/2014Suzanne Sawochka HooperEVPSell1,852$178.79$331,119.08View SEC Filing  
12/1/2014Patrick G EnrightDirectorSell10,000$172.74$1,727,400.00View SEC Filing  
11/24/2014Jeffrey K TobiasCMOSell4,598$170.12$782,211.76View SEC Filing  
11/7/2014Iain McgillSVPSell7,066$172.03$1,215,563.98View SEC Filing  
10/10/2014Jeffrey K TobiasCMOSell1,000$154.04$154,040.00View SEC Filing  
10/6/2014Patrick G EnrightDirectorSell10,000$160.56$1,605,600.00View SEC Filing  
9/25/2014Seamus MulliganDirectorSell50,000$163.16$8,158,000.00View SEC Filing  
9/24/2014Seamus MulliganDirectorSell35,294$163.70$5,777,627.80View SEC Filing  
9/12/2014Jeffrey K TobiasCMOSell1,000$171.22$171,220.00View SEC Filing  
9/11/2014Karen J WilsonSVPSell3,000$175.00$525,000.00View SEC Filing  
9/11/2014Seamus MulliganDirectorSell50,000$175.00$8,750,000.00View SEC Filing  
9/9/2014Bruce C CozaddCEOSell5,000$170.32$851,600.00View SEC Filing  
9/8/2014Karen J WilsonSVPSell2,500$170.00$425,000.00View SEC Filing  
9/8/2014Suzanne Sawochka HooperEVPSell1,852$168.00$311,136.00View SEC Filing  
8/12/2014Bruce C CozaddCEOSell5,000$133.15$665,750.00View SEC Filing  
8/12/2014Suzanne Sawochka HooperEVPSell1,185$133.15$157,782.75View SEC Filing  
8/11/2014Jeffrey K TobiasCMOSell4,933$135.42$668,026.86View SEC Filing  
7/8/2014Bruce C CozaddCEOSell5,000$155.00$775,000.00View SEC Filing  
7/8/2014Suzanne Sawochka HooperEVPSell1,853$155.00$287,215.00View SEC Filing  
7/7/2014Karen J WilsonSVPSell2,500$165.00$412,500.00View SEC Filing  
6/25/2014Seamus MulliganDirectorSell50,000$149.69$7,484,500.00View SEC Filing  
6/20/2014Russell J CoxCOOSell2,000$155.00$310,000.00View SEC Filing  
6/17/2014Fintan KeeganEVPSell3,750$150.00$562,500.00View SEC Filing  
6/10/2014Bruce C CozaddCEOSell5,000$142.34$711,700.00View SEC Filing  
5/16/2014Jeffrey TobiasCMOSell1,000$128.01$128,010.00View SEC Filing  
5/13/2014Bruce CozaddCEOSell5,000$128.92$644,600.00View SEC Filing  
4/17/2014Rick WinninghamDirectorSell27,500$140.00$3,850,000.00View SEC Filing  
4/14/2014Jeffrey TobiasCMOSell3,000$128.54$385,620.00View SEC Filing  
4/8/2014Bruce CozaddCEOSell5,000$123.18$615,900.00View SEC Filing  
3/10/2014Jeffrey TobiasCMOSell3,000$152.99$458,970.00View SEC Filing  
3/6/2014Fintan KeeganEVPSell4,640$159.90$741,936.00View SEC Filing  
3/4/2014Seamus MulliganDirectorSell550,000$156.25$85,937,500.00View SEC Filing  
3/3/2014Patrick EnrightDirectorSell559,628$152.39$85,281,710.92View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
DateHeadline
benzinga.com logoThe Drug Price Increase Debate: Separating The Winners From The Losers (NASDAQ:JAZZ)
www.benzinga.com - September 27 at 5:43 PM
streetinsider.com logoJazz Pharmaceuticals (JAZZ) Completes Enrollment of JZP-110 Phase 3 as Obstructive Sleep Apnea Treatment (NASDAQ:JAZZ)
www.streetinsider.com - September 27 at 5:43 PM
prnewswire.com logoJazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 Evaluating ... - PR Newswire (press release) (NASDAQ:JAZZ)
www.prnewswire.com - September 27 at 10:21 AM
News IconJazz Pharmaceuticals Announces That Patient Enrollment is Complete... (NASDAQ:JAZZ)
www.aboutpharma.com - September 26 at 5:49 PM
finance.yahoo.com logoJazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 … (NASDAQ:JAZZ)
finance.yahoo.com - September 26 at 5:49 PM
publicnow.com logoJazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 Evaluating Excessive Sleepiness in Obstructive Sleep Apnea (NASDAQ:JAZZ)
www.publicnow.com - September 26 at 5:49 PM
fool.com logo3 Top Biotech Stocks to Buy on Sale (NASDAQ:JAZZ)
www.fool.com - September 26 at 5:49 PM
realistinvestor.com logoJazz Pharmaceuticals plc (NASDAQ:JAZZ)'s Accounts Payable Is $28.406 - RealistInvestor.com (NASDAQ:JAZZ)
www.realistinvestor.com - September 23 at 8:52 AM
finance.yahoo.com logoNext Year Setting Up To Be Smooth For Jazz Pharmaceuticals (NASDAQ:JAZZ)
finance.yahoo.com - September 22 at 8:55 AM
benzinga.com logoNext Year Setting Up To Be Smooth For Jazz Pharmaceuticals - Benzinga (NASDAQ:JAZZ)
www.benzinga.com - September 21 at 3:58 PM
News IconHot Biotech Stocks Recap: Corcept Therapeutics Incorporated ... - The Voice Registrar (NASDAQ:JAZZ)
voiceregistrar.com - September 19 at 5:45 PM
marketwatch.com logoYes, you are paying more a lot more for prescription drugs (and not just the EpiPen) (NASDAQ:JAZZ)
www.marketwatch.com - September 17 at 10:17 AM
News IconJazz Pharmaceuticals PLC (NASDAQ: JAZZ) Buy Rating Reiterated ... - BNB Daily (blog) (NASDAQ:JAZZ)
www.baseball-news-blog.com - September 16 at 9:39 AM
News IconGood or Bad? Pharma Bro Thinks Jazz Pharma Could be Worth $20 Billion, Calls Mast Therapeutics 'Worthless' (NASDAQ:JAZZ)
www.biospace.com - September 13 at 10:32 AM
News IconPlacing Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Under the Microscope - Post News (NASDAQ:JAZZ)
www.kentuckypostnews.com - September 9 at 10:28 AM
prnewswire.com logoJazz Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference - PR Newswire (press release) (NASDAQ:JAZZ)
www.prnewswire.com - September 8 at 9:38 AM
News IconLeerink Swann Reiterates Outperform at Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) - BNB Daily (blog) (NASDAQ:JAZZ)
www.baseball-news-blog.com - September 8 at 9:38 AM
publicnow.com logoJazz Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference (NASDAQ:JAZZ)
www.publicnow.com - September 7 at 5:52 PM
forbes.com logo3 Hottest Cancer Biotech Acquisition Targets After Medivation (NASDAQ:JAZZ)
www.forbes.com - September 6 at 5:42 PM
benzinga.com logoJanney Initiates Jazz Pharma At Neutral, Cites Potential Competition For 'Blockbuster Narcolepsy Franchise' - Benzinga (NASDAQ:JAZZ)
www.benzinga.com - August 26 at 5:35 PM
benzinga.com logoJanney Initiates Jazz Pharma At Neutral, Cites Potential Competition For 'Blockbuster Narcolepsy Franchise' (NASDAQ:JAZZ)
www.benzinga.com - August 25 at 5:47 PM
bizjournals.com logoGeneric Advair among upcoming drugs key to higher sales at former Roxane Labs (NASDAQ:JAZZ)
www.bizjournals.com - August 24 at 5:37 PM
forbes.com logoJazz Pharmaceuticals is Now Oversold (JAZZ) (NASDAQ:JAZZ)
www.forbes.com - August 24 at 5:37 PM
capitalcube.com logoETF’s with exposure to Jazz Pharmaceuticals Plc : August 24, 2016 (NASDAQ:JAZZ)
www.capitalcube.com - August 24 at 5:36 PM
investornewswire.com logoJazz Pharmaceuticals plc (NASDAQ:JAZZ) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:JAZZ)
www.investornewswire.com - August 24 at 8:52 AM
marketrealist.com logoPfizer’s Medivation Acquisition: What You Need to Know (NASDAQ:JAZZ)
marketrealist.com - August 23 at 10:08 AM
nasdaq.com logoPPH's Holdings Imply 16% Gain Potential (NASDAQ:JAZZ)
www.nasdaq.com - August 22 at 10:20 AM
News IconDirector of Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Berns Paul L, sells 633 shares worth $86,373 (NASDAQ:JAZZ)
empowerednews.net - August 19 at 8:46 AM
News IconNew report: Jazz Pharmaceuticals Plc (JAZZ) - strategic and financial SWOT analysis review (NASDAQ:JAZZ)
www.whatech.com - August 19 at 8:46 AM
realistinvestor.com logoJazz Pharmaceuticals plc (NASDAQ:JAZZ) Reports Accounts Payable Of $28.406 - RealistInvestor.com (NASDAQ:JAZZ)
www.realistinvestor.com - August 18 at 5:46 PM
finance.yahoo.com logoJAZZ PHARMACEUTICALS PLC Financials (NASDAQ:JAZZ)
finance.yahoo.com - August 18 at 5:46 PM
investornewswire.com logoWill Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hit $210 Price Target? - Investor Newswire (NASDAQ:JAZZ)
www.investornewswire.com - August 18 at 8:46 AM
streetinsider.com logoForm 4 Jazz Pharmaceuticals For: Aug 11 Filed by: Winningham Rick E (NASDAQ:JAZZ)
www.streetinsider.com - August 16 at 8:58 AM
capitalcube.com logoETF’s with exposure to Jazz Pharmaceuticals Plc : August 12, 2016 (NASDAQ:JAZZ)
www.capitalcube.com - August 12 at 5:50 PM
247wallst.com logoWhy This Analyst Sees Huge Upside for Valeant and 2 More Specialty Pharmas (NASDAQ:JAZZ)
247wallst.com - August 12 at 8:54 AM
benzinga.com logoJazz Pharmaceuticals Remains A Buy At Deutsche Bank Post Q2 Report (NASDAQ:JAZZ)
www.benzinga.com - August 11 at 5:58 PM
capitalcube.com logoJazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:JAZZ)
www.capitalcube.com - August 11 at 5:58 PM
capitalcube.com logoJazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : JAZZ-US : August 11, 2016 (NASDAQ:JAZZ)
www.capitalcube.com - August 11 at 8:50 AM
schaeffersresearch.com logoAnalyst Update: Foamix Pharmaceuticals Ltd, Jazz Pharmaceuticals plc, and Healthways, Inc. - Schaeffers Research (blog) (NASDAQ:JAZZ)
www.schaeffersresearch.com - August 10 at 6:02 PM
benzinga.com logoJazz Pharmaceuticals Remains On Goldman's Buy List - Benzinga (NASDAQ:JAZZ)
www.benzinga.com - August 10 at 6:02 PM
finance.yahoo.com logoJazz Pharmaceuticals Remains On Goldman's Buy List (NASDAQ:JAZZ)
finance.yahoo.com - August 10 at 6:02 PM
thestreet.com logoJazz Pharmaceuticals (JAZZ) Stock Tumbles on Q2 Miss, Guidance (NASDAQ:JAZZ)
www.thestreet.com - August 10 at 6:02 PM
sg.finance.yahoo.com logoJazz misses Street 2Q forecasts (NASDAQ:JAZZ)
sg.finance.yahoo.com - August 10 at 8:41 AM
finance.yahoo.com logoEdited Transcript of JAZZ earnings conference call or presentation 9-Aug-16 8:30pm GMT (NASDAQ:JAZZ)
finance.yahoo.com - August 10 at 8:41 AM
finance.yahoo.com logoJazz (JAZZ) Q2 Earnings Up Y/Y, Lowers Earnings Outlook (NASDAQ:JAZZ)
finance.yahoo.com - August 10 at 8:41 AM
twst.com logoJazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Second Quarter 2016 Financial Results (NASDAQ:JAZZ)
www.twst.com - August 9 at 5:56 PM
twst.com logoJazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Second Quarter 2016 Financial Results (NASDAQ:JAZZ)
www.twst.com - August 9 at 5:56 PM
biz.yahoo.com logoJAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:JAZZ)
biz.yahoo.com - August 9 at 5:56 PM
publicnow.com logoJazz Pharmaceuticals Announces Second Quarter 2016 Financial Results (NASDAQ:JAZZ)
www.publicnow.com - August 9 at 5:56 PM
biz.yahoo.com logoQ2 2016 Jazz Pharmaceuticals PLC Earnings Release - After Market Close (NASDAQ:JAZZ)
biz.yahoo.com - August 9 at 8:46 AM

Social

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff